Blogs & News
Xcellon Biologics Acquires GMP Manufacturing Facility from NextCure, Becoming an End-to-End CRDMO for Next-Generation Bioconjugates and Complex Biologics
- Press Release
Acquisition of the GMP biologics manufacturing facility expands Xcellon’s integrated capabilities from discovery through clinical supply and strengthens U.S. biomanufacturing
ADC Manufacturing Capacity Is What Pharma Is Really Buying
- Blog
BioBuzz features Xcellon Biologics and COO Yuk Chiu in a look at why ADC manufacturing capacity is 2026's real industry bottleneck.
Xcellon Biologics Launches XSpec™, a New Bioconjugation Configurator
- Press Release
Xcellon Biologics has launched XSpec™, a bioconjugation configurator that streamlines early-stage program design for ADCs and other targeted therapeutics.
Linden Lake Labs Portfolio Company CrossBridge Bio to Be Acquired by Eli Lilly and Company
- Press Release
CrossBridge Bio to be acquired by Eli Lilly and Company for up to $300 million, marking an early platform milestone for Linden Lake Labs.
Xcellon Biologics Launches Xcellerate Program to Support Early-Stage Biotech Innovation
- Press Release
Xcellon Biologics launches Xcellerate, a program designed to help early-stage biotech companies accelerate ADC development and navigate the toughest phase between proof-of-concept and funding.
IntoCell and Xcellon Biologics Partner to Expand Access to Next-Generation ADC Technologies
- Press Release
Xcellon Biologics partners with IntoCell to expand linker-payload toolbox
Upcoming Events
Xcellon is sponsoring World ADC 2026
Xcellon Biologics is proud to sponsor the World ADC 2026. Come visit our booth and see our latest development in conjugation technologies and gene to IND service offerings!
- 10/12/2026
- — 10/15/2026
Partner
With Us
Partner With Us
Xcellon Biologics is backed by successful biotech entrepreneurs and professionals from top pharmaceutical and CDMO companies including Lonza, Abzena, Amgen, MedImmune, AstraZeneca, BioNTech, Seattle Genetics, and Immunomedics.
We collaborate with leading innovators and global partners to accelerate biopharmaceutical breakthroughs while maintaining the highest quality and regulatory standards.
